You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 10,076,523


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,076,523
Title:HSPC-sparing treatments for RB-positive abnormal cellular proliferation
Abstract: This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
Inventor(s): Strum; Jay Copeland (Hillsborough, NC), Bisi; John Emerson (Chapel Hill, NC), Roberts; Patrick Joseph (Durham, NC), Tavares; Francis Xavier (Durham, NC)
Assignee: G1 Therapeutics, Inc. (Research Triangle Park, NC)
Application Number:15/387,083
Patent Claims:1. A method for treating retinoblastoma (Rb)-positive breast cancer in a host comprising administering an effective amount of a compound to a host in need thereof, wherein the compound is ##STR00327## or a pharmaceutically acceptable salt thereof, and wherein the compound is administered to the host at least once a day for 28 or more continuous days.

2. The method of claim 1, wherein the host is a human.

3. The method of claim 2, wherein the compound is administered orally.

4. The method of claim 2, further comprising administering to the host at least one additional chemotherapeutic agent during the treatment regimen.

5. The method of claim 2, wherein the breast cancer is estrogen-receptor positive.

6. The method of claim 1, wherein the compound is administered at least once a day for 35 or more continuous days.

7. The method of claim 4, wherein the additional chemotherapeutic agent is selected from tamoxifen, letrozole, anastrozole, toremifene, and trastuzumab.

8. The method of claim 2, wherein the compound is administered once a day.

9. The method of claim 4, wherein the additional chemotherapeutic agent is tamoxifen.

10. The method of claim 4, wherein the additional chemotherapeutic agent is letrozole.

11. The method of claim 4, wherein the additional chemotherapeutic agent is anastrozole.

12. The method of claim 4, wherein the additional chemotherapeutic agent is toremifene.

13. The method of claim 4, wherein the additional chemotherapeutic agent is trastuzumab.

14. The method of claim 2, wherein the Rb-positive breast cancer is estrogen receptor positive, HER2-negative advanced breast cancer.

15. The method of claim 2, wherein the Rb-positive breast cancer is HER2-positive breast cancer.

Details for Patent 10,076,523

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2033-03-15
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2033-03-15
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 02/28/2019 ⤷  Try a Trial 2033-03-15
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.